Dominic Tilden


Dominic Tilden

BCom; MPH.

Dominic Tilden is a health economist with over 20 years practical experience in the design, development and implementation of health economic evaluations. The health economic evaluations have taken the form of cost-minimisation, cost-effectiveness, cost-utility and cost-benefit analyses. This experience has been gained across a large variety of therapeutic areas including oncology, cardiovascular diseases, diabetes, schizophrenia, ADHD, infectious diseases, osteoarthritis, thrombosis, transplantation, diagnostics and screening.

Dominic Tilden has been an integral component of teams developing reimbursement applications across the world. He has developed and implemented creative and analytical strategies, managed multi-disciplinary teams and prepared submission dossiers for the communication of sound health technology assessment and health economic arguments to reimbursement authorities in Australia, England, Wales, Scotland and many European countries. Since 1999, Dominic has been involved in and/or responsible for: over 300 submissions to the Pharmaceutical Benefits Advisory Committee (PBAC) in Australia; over 6 submissions to the National Institute for Health and clinical Excellence (NICE) in England and Wales and more than 5 submissions to the Scottish Medicines Consortium (SMC). Health economic evaluations completed by Dominic Tilden have been used in reimbursement applications in Canada, Finland, France, Germany, Holland, Norway, Portugal, Sweden and more.

Dominic has developed models using first and second order Monte Carlo simulation, discrete event `simulation, decision-analytic models, Markov and semi-Markov models and probabilistic. These models are developed in DATA software (by TreeAge) or with advanced Excel skills including visual basic (if necessary). Dominic has been previously employed by TreeAge software as a trainer for their DATA software training courses.